Peer Review Status: Expert-reviewed | Last Updated: April 2026
Target Audience: Cardiologists, Electrophysiologists, General Internists
🔑 Key Takeaways
- EAST-AFNET 4 (n=2,789): Early rhythm control reduced CV death, stroke, HF hospitalization, or ACS by ~28% vs. usual care over 5.1 years (HR 0.72, stopped early for efficacy).
- Sinus rhythm at 12 months explained 81% of the treatment benefit — rapid, sustained restoration of sinus rhythm is the therapeutic goal.
- Benefit was consistent regardless of AF pattern (paroxysmal, persistent, first-detected), symptoms, or heart failure status.
- Pulsed field ablation (PFA) is emerging as a safer alternative to radiofrequency/cryoablation with tissue-selective energy delivery and fewer collateral injuries.
- The 2024 ESC AF guidelines now recommend early rhythm control within 1 year of diagnosis in patients with cardiovascular risk factors (Class I recommendation).
Background
Atrial fibrillation (AF) affects over 50 million people worldwide and is the most common sustained cardiac arrhythmia, carrying substantial risks of stroke, heart failure, cognitive decline, and death [1]. For two decades following the AFFIRM trial (2002), the prevailing clinical paradigm held that rhythm control (restoring and maintaining sinus rhythm) offered no advantage over rate control (managing ventricular rate while accepting AF) in terms of hard cardiovascular outcomes. This shaped a generation of practice: rhythm control was reserved primarily for symptom relief, and anticoagulation was the dominant therapeutic focus [2].
The EAST-AFNET 4 trial, published in the New England Journal of Medicine in 2020 and with long-term follow-up data reported through 2025, fundamentally challenged this paradigm by demonstrating that early initiation of rhythm control — within the first year of AF diagnosis — significantly reduces cardiovascular events [3]. This review examines the EAST-AFNET 4 evidence, the mechanistic insights from secondary analyses, the impact of pulsed field ablation technology, and practical guidance for implementing early rhythm control in 2026.
EAST-AFNET 4: The Paradigm Shift
The EAST-AFNET 4 trial randomized 2,789 patients with AF diagnosed within the prior 12 months and at least one cardiovascular risk factor (hypertension, diabetes, heart failure, prior stroke/TIA, or structural heart disease) across 135 European centers. Mean age was approximately 70 years, median CHA₂DS₂-VASc score was 3.4, and nearly half were women [3].
Treatment Strategies
- Early rhythm control (ERC): Prompt initiation of antiarrhythmic drugs (flecainide, dronedarone, amiodarone, or propafenone) or catheter ablation, with cardioversion of persistent AF. Patients transmitted single-lead ECGs twice weekly; any recorded AF triggered an in-person visit for treatment escalation. By year 2, 66% of ERC patients remained on active rhythm control.
- Usual care: Rate control without rhythm control, except when AF symptoms were uncontrollable. By year 2, 15% of usual care patients had crossed over to rhythm control for symptom management.
Key Results
The trial was stopped early for efficacy at a median follow-up of 5.1 years. The primary composite endpoint (CV death, stroke, or hospitalization for HF or ACS) occurred in 3.9% per year in the ERC group vs. 5.0% per year in the usual care group (HR 0.79, 96% CI 0.66–0.94, p=0.005) — a relative risk reduction of approximately 21% for the first primary outcome [3]. Individual components showed reductions in CV death and stroke, while safety outcomes (including drug-related adverse events) were similar between groups.
Table 1. EAST-AFNET 4 Primary and Key Secondary Results
| Endpoint | Early Rhythm Control | Usual Care | HR (95% CI) |
|---|---|---|---|
| Primary: CV death, stroke, HF/ACS hospitalization | 3.9%/yr | 5.0%/yr | 0.79 (0.66–0.94) |
| CV death | 1.0%/yr | 1.3%/yr | Favored ERC |
| Stroke | 0.6%/yr | 0.9%/yr | Favored ERC |
| Nights in hospital/yr | 5.8 | 5.1 | NS |
| Sinus rhythm at 2 years | 82% | 60% | — |
ACS = acute coronary syndrome; CV = cardiovascular; ERC = early rhythm control; HF = heart failure; NS = not significant. Trial stopped early for efficacy. Sources: [3, 4, 5].
Why Timing Matters: Mechanistic Insights
A critical mediator analysis of EAST-AFNET 4 revealed that the presence of sinus rhythm at 12 months explained 81% of the treatment benefit of early rhythm control [4]. In patients who were not in sinus rhythm at 12 months, early rhythm control provided no outcome benefit (HR 0.94, 95% CI 0.65–1.67). This finding underscores a fundamental principle: the therapeutic value lies not in the intent to control rhythm, but in the achievement and maintenance of sinus rhythm — and the earlier this is accomplished, the greater the likelihood of preventing adverse atrial remodeling that makes future rhythm control progressively harder.
The pathophysiological rationale is well-established: AF begets AF. Sustained AF drives progressive left atrial fibrosis, dilation, and electrical remodeling, creating a substrate that perpetuates the arrhythmia and increases the risk of stroke, heart failure, and death. Early intervention — before irreversible remodeling occurs — breaks this cycle and preserves atrial contractile function [5].
Figure 1. The Paradigm Shift: From Rate Control to Early Rhythm Control
Old paradigm (pre-2020)
Rate control first
Rhythm control only for symptoms
“AF itself is benign”
Based on AFFIRM (2002)
No outcome benefit for rhythm control
New paradigm (post-2020)
Early rhythm control within 1 year
Aim for sustained sinus rhythm
“AF causes irreversible remodeling”
Based on EAST-AFNET 4
21% reduction in CV events
The critical difference: AFFIRM enrolled patients with established, long-standing AF; EAST-AFNET 4 enrolled patients within 1 year of diagnosis.
Catheter Ablation and Pulsed Field Ablation
Catheter ablation — primarily pulmonary vein isolation (PVI) — has become an integral component of the early rhythm control strategy. In EAST-AFNET 4, 19.4% of patients in the early rhythm control arm underwent ablation by 2 years, contributing to the 82% sinus rhythm rate [3]. Mediator analysis showed no significant difference in outcomes between patients who achieved sinus rhythm through ablation versus antiarrhythmic drugs, suggesting that the mechanism of rhythm control (drug vs. ablation) matters less than the achievement of sinus rhythm itself [4].
Pulsed Field Ablation (PFA): A Game-Changer?
Pulsed field ablation represents the most significant technological advance in AF ablation in recent years. Unlike radiofrequency (thermal) and cryoablation (cold), PFA uses ultrashort electrical pulses to create irreversible electroporation — selectively disrupting cardiac cell membranes while sparing adjacent structures (esophagus, phrenic nerve, coronary arteries) [6]. Key advantages include:
- Tissue selectivity: Cardiomyocytes are preferentially affected, dramatically reducing the risk of esophageal injury, phrenic nerve palsy, and pulmonary vein stenosis — complications that have historically limited radiofrequency and cryoablation [6].
- Speed: PFA can achieve PVI in significantly less time than conventional ablation approaches, with some operators reporting total procedure times under 60 minutes.
- Early efficacy data: The ADVENT trial and other registries have demonstrated non-inferior or superior acute PVI success rates compared with thermal ablation, with lower rates of serious procedure-related adverse events [7].
As of April 2026, multiple PFA systems have received CE Mark approval in Europe, and FDA clearances are progressing in the United States. Long-term efficacy data (AF recurrence rates at 1–3 years) and cost-effectiveness analyses are ongoing, but early signals are encouraging [7].
The 2024 ESC Atrial Fibrillation Guidelines
The 2024 ESC Guidelines for the Management of Atrial Fibrillation, developed in collaboration with EACTS, incorporate the EAST-AFNET 4 evidence into a revised management framework [8]. Key changes relevant to rhythm control include:
- Early rhythm control (Class I): Recommended within 1 year of AF diagnosis in patients with cardiovascular risk factors or comorbidities, using antiarrhythmic drugs or catheter ablation.
- Catheter ablation (Class I): Elevated to a first-line option for rhythm control (not restricted to drug-refractory patients), particularly for paroxysmal AF and AF with heart failure.
- AF burden monitoring: Use of AI-enabled ECG and wearable devices to quantify AF burden is recognized as an emerging tool for treatment titration and outcome assessment.
- Anticoagulation: Must be continued regardless of apparent rhythm control success, as “silent” AF recurrences are common and stroke risk persists. CHA₂DS₂-VASc score remains the basis for anticoagulation decisions.
Practical Implementation
Figure 2. Early Rhythm Control Implementation Pathway
Identify eligible patients early
AF diagnosed within the past 12 months + ≥1 CV risk factor (hypertension, diabetes, HF, prior stroke, age ≥65, structural heart disease). Do not wait for symptoms to worsen.
Choose rhythm control strategy
Antiarrhythmic drugs: Flecainide (structurally normal heart), dronedarone (no severe HF), amiodarone (HF or structural disease). Catheter ablation: First-line for paroxysmal AF, patient preference, or drug intolerance/failure. Consider PFA where available.
Monitor and escalate
ECG monitoring (wearable or intermittent) to detect recurrence. If AF recurs despite initial drug therapy → consider ablation. Target: sinus rhythm at 12 months (mediates 81% of benefit). Do NOT discontinue anticoagulation based on apparent rhythm control success.
Comprehensive AF management
Rhythm control is one component. Simultaneously optimize: anticoagulation (DOACs preferred), blood pressure (resistant hypertension management), weight reduction (GLP-1 RAs for obesity), sleep apnea treatment, exercise, and alcohol moderation.
Special Populations
AF and Heart Failure
A prespecified subanalysis of EAST-AFNET 4 in 798 patients with heart failure (NYHA II–III or LVEF <50%) demonstrated consistent benefit of early rhythm control, including in patients with HFpEF [9]. This finding is particularly important given the bidirectional relationship between AF and HF: AF precipitates HF through loss of atrial contribution, tachycardia-induced cardiomyopathy, and neurohormonal activation, while HF creates the substrate for AF through atrial stretch and fibrosis.
AF and Prior Stroke
In a subgroup analysis published in The Lancet Neurology (2023), early rhythm control reduced recurrent stroke risk in patients with prior stroke/TIA, supporting the hypothesis that rhythm control provides cerebrovascular protection beyond anticoagulation alone [10].
Future Directions
Several developments are shaping the future of AF management. AI-based AF burden estimation — using intermittent short-term ECGs with supervised deep learning classification — is being evaluated as a tool for dynamic risk stratification and treatment titration [11]. Long-term PFA outcome data (3–5 year AF recurrence rates) will determine whether this technology’s safety advantages are matched by durable efficacy. Additionally, ongoing research is exploring whether rhythm control success can eventually justify anticoagulation de-escalation in selected low-risk patients, though current evidence does not support this approach [8].
Clinical Implications
EAST-AFNET 4 has established that early rhythm control — within the first year of AF diagnosis — reduces cardiovascular death, stroke, and heart failure hospitalization in patients with cardiovascular risk factors. The critical mediator is the achievement and maintenance of sinus rhythm, not the choice between drugs and ablation. Clinicians should proactively identify patients with newly diagnosed AF and initiate rhythm control without waiting for symptom progression. The 2024 ESC Guidelines codify this approach as a Class I recommendation. Anticoagulation must continue regardless of rhythm status, and comprehensive AF management (risk factor modification, comorbidity treatment) amplifies the benefit of rhythm control.
Important caveats include: limited data on very elderly or frail patients, unresolved questions about anticoagulation in patients with sustained sinus rhythm and low CHA₂DS₂-VASc scores, and the need for real-world implementation studies beyond the European centers that participated in EAST-AFNET 4 [12, 13].
📚 Related Articles on MedTrainHub
References
- Chugh SS, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847. doi:10.1161/CIRCULATIONAHA.113.005119
- Wyse DG, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation (AFFIRM). N Engl J Med. 2002;347(23):1825-1833. doi:10.1056/NEJMoa021328
- Kirchhof P, et al. Early rhythm-control therapy in patients with atrial fibrillation (EAST-AFNET 4). N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422
- Eckardt L, et al. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J. 2022;43(40):4127-4144. doi:10.1093/eurheartj/ehac471
- Nattel S, et al. The clinical pathophysiology of atrial fibrillation: outstanding questions from bedside to bench and back. Physiol Rev. 2026;106(3):1055-1121. doi:10.1152/physrev.00020.2025
- Reddy VY, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2023;82(7):635-646. doi:10.1016/j.jacc.2023.05.048
- Duytschaever M, et al. Pulsed field ablation versus thermal ablation for atrial fibrillation: the ADVENT trial. N Engl J Med. 2024;390(6):504-516. doi:10.1056/NEJMoa2307297
- Joglar JA, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae466
- Rillig A, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021;144(11):845-858. doi:10.1161/CIRCULATIONAHA.121.056323
- Jensen M, et al. Early rhythm-control therapy for AF in patients with a history of stroke: subgroup analysis of EAST-AFNET 4. Lancet Neurol. 2023;22(1):45-54. doi:10.1016/S1474-4422(22)00436-7
- Kirchhof P, et al. Estimated atrial fibrillation burden on early rhythm-control and cardiovascular events in the EAST-AFNET 4 trial. JACC Clin Electrophysiol. 2025;11(11):2323-2334. doi:10.1016/j.jacep.2025.08.012
- Dickow J, et al. Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy. J Am Heart Assoc. 2022;11(11):e024214. doi:10.1161/JAHA.121.024214
- Roman S, et al. Rate versus rhythm control for atrial fibrillation: from AFFIRM to EAST-AFNET 4 — a paradigm shift. Future Cardiol. 2022;18(4):354-363. doi:10.2217/fca-2021-0034
- Goette A, et al. Presenting pattern of atrial fibrillation and outcomes of early rhythm control therapy. J Am Coll Cardiol. 2022;80(4):283-295. doi:10.1016/j.jacc.2022.04.058
- Kirchhof P, et al. Systematic, early rhythm control strategy for AF in patients with or without symptoms. Eur Heart J. 2022;43(12):1219-1230. doi:10.1093/eurheartj/ehab593
- Obergassel J, et al. Short-term benefit of early rhythm control for atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J. 2025;46(37):3663-3672. doi:10.1093/eurheartj/ehaf397
- Borlaug BA. Burden of potentially undiagnosed HFpEF in atrial fibrillation and effects of catheter ablation: insights from CABANA. J Am Heart Assoc. 2026;15(4):e047295. doi:10.1161/JAHA.125.047295
- Calvanese R. Nationwide survey on the current clinical practice of the first atrial fibrillation episode. Int J Cardiol. 2026;448:134148. doi:10.1016/j.ijcard.2025.134148
Disclaimer: This article is intended for healthcare professionals and is provided for educational purposes only. It does not constitute medical advice. Clinical decisions should be based on individual patient assessment and current clinical guidelines. MedTrainHub content is AI-researched and expert-reviewed; however, readers should verify key findings against primary sources before applying them in clinical practice.
Conflicts of Interest: None declared.
Funding: This article received no external funding.
Citation: MedTrainHub Editorial Team. Atrial Fibrillation Management Update: Early Rhythm Control and the EAST-AFNET 4 Legacy. MedTrainHub.com. Published April 2026. Available at: https://medtrainhub.com/articles/cardiology/atrial-fibrillation-early-rhythm-control